• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SD filed by United Therapeutics Corporation

    5/30/25 4:30:38 PM ET
    $UTHR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $UTHR alert in real time by email
    SD 1 tm2516426d1_sd.htm FORM SD

     

     

      

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

     

    FORM SD

     

    SPECIALIZED DISCLOSURE REPORT

     

    United Therapeutics Corporation

    (Exact Name of Registrant as Specified in Charter)

     

    Delaware   000-26301   52-1984749
    (State or Other   (Commission   (I.R.S. Employer
    Jurisdiction of   File Number)   Identification Number)
    Incorporation or Organization)        

     

    1000 Spring Street    
    Silver Spring, MD   20910
    (Address of Principal Executive Offices)   (Zip Code)

     

    James Edgemond, (301) 608-9292

    (Name and telephone number, including area code, of the

    person to contact in connection with this report)

     

    Check the appropriate box to indicate the rule pursuant to which this form is being filed, and provide the period to which the information in this form applies:

     

    xRule 13p-1 under the Securities Exchange Act (17 CFR 240.13p-1) for the reporting period from January 1 to December 31, 2024.

     

    ¨Rule 13q-1 under the Securities Exchange Act (17 CFR 240.13q-1) for the fiscal year ended ______.

     

     

      

     

     

      

    Item 1.01  Conflict Minerals Disclosure and Report.

     

    United Therapeutics Corporation (UT) is committed to social responsibility in the supply chain of its materials, including considerations and requirements relating to the environment, safety, health, and human rights. This includes efforts to comply with rules and regulations promulgated by the U.S. Securities and Exchange Commission to implement Section 1502 of the Dodd-Frank Wall Street Reform and Consumer Protection Act (the Conflict Mineral Rules). These rules require UT to conduct a reasonable country of origin inquiry that is reasonably designed to determine whether Conflict Minerals (defined below) necessary to the functionality or production of products manufactured or contracted to be manufactured by UT originated in Covered Countries (defined below) or came from recycled or scrap sources.

     

    The Conflict Mineral Rules define Conflict Minerals as cassiterite, columbite-tantalite, gold, wolframite, and their derivatives (which are limited to tin, tantalum, and tungsten). Covered Countries is defined as the Democratic Republic of the Congo and its adjoining countries.

     

    In accordance with the Conflict Mineral Rules, UT has determined that it has two products that contain Conflict Minerals (the Relevant Products). UT has conducted a good faith, reasonable country of origin inquiry (as described below) and determined that UT has no reason to believe that the Conflict Minerals in the Relevant Products may have originated in the Covered Countries. Therefore, UT is not required to provide a conflict minerals report with respect to the Relevant Products.

     

    UT contracts to manufacture the Relevant Products and does not directly purchase Conflict Minerals included in the products. UT’s reasonable country of origin inquiry included an examination of the bill of materials and approved supplier list for the Relevant Products. Based on that review, UT conducted a comprehensive inquiry of a total of 109 companies, representing all UT’s direct suppliers relating to the Relevant Products and their respective first and second-tier component suppliers. UT requested each supplier to provide a written statement regarding its use of Conflict Minerals to determine whether any Conflict Minerals originating in Covered Countries (and not from scrap or recycled sources) were incorporated into the Relevant Products. UT received responses from all of these suppliers, and, based on their responses, had no reason to believe Conflict Minerals necessary to the functionality or production of the Relevant Products either: (1) originated from Covered Countries; or (2) were sourced from a smelter that the Responsible Business Alliance had determined to be non-compliant with its Responsible Minerals Initiative assessment protocols.

     

    Conflict Minerals Disclosure

     

    This Conflict Minerals Disclosure is publicly available on UT’s website, located at http://ir.unither.com/corporate-governance.

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the duly authorized undersigned.

     

      UNITED THERAPEUTICS CORPORATION
         
    Date: May 30, 2025 By: /s/ Paul A. Mahon
      Name: Paul A. Mahon
      Title: General Counsel

     

     

    Get the next $UTHR alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $UTHR

    DatePrice TargetRatingAnalyst
    6/2/2025$405.00Overweight
    Cantor Fitzgerald
    4/25/2025Overweight → Equal Weight
    Wells Fargo
    4/21/2025$314.00Underperform → Neutral
    BofA Securities
    7/11/2024$310.00 → $321.00Overweight → Equal-Weight
    Morgan Stanley
    2/12/2024$213.00 → $215.00Sell → Neutral
    Goldman
    2/5/2024$330.00Outperform
    Leerink Partners
    12/8/2023$309.00Overweight
    Wells Fargo
    12/6/2022$320.00Buy
    UBS
    More analyst ratings

    $UTHR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the European Respiratory Society Congress

    Results of the successful phase 3 TETON-2 study of inhaled treprostinil in idiopathic pulmonary fibrosis will be presented in an oral presentation United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that recent research across its commercial and development portfolio will be presented at the European Respiratory Society (ERS) Congress in Amsterdam, Netherlands on September 27 - October 1, 2025. "On the heels of the remarkable topline results announced earlier this month, we are excited to present additional analyses from the TETON-2 study at ERS this year," said Andrew Nelsen, PharmD, Vice President, Global Medical Affairs at United Therapeutics

    9/12/25 7:00:00 AM ET
    $UTHR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    United Therapeutics Corporation Announces TETON-2 Pivotal Study of Tyvaso® Meets Primary Endpoint for the Treatment of Idiopathic Pulmonary Fibrosis

    Positive results were observed across all subgroups Study meets several key secondary endpoints with statistical significance United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that its TETON-2 study evaluating the use of nebulized Tyvaso® (treprostinil) Inhalation Solution for the treatment of idiopathic pulmonary fibrosis (IPF) met its primary efficacy endpoint of demonstrating improvement in absolute forced vital capacity (FVC) relative to placebo. Tyvaso demonstrated superiority over placebo for the change in absolute FVC by 95.6 mL (Hodges-Lehmann estimate, p <0.0001) from baseline to week 52 in patients with IPF. Benefits of Tyvaso were

    9/2/25 7:00:00 AM ET
    $UTHR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    United Therapeutics Corporation to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference

    United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that James Edgemond, Chief Financial Officer and Treasurer, will provide an overview and update on the company's operations during a fireside chat session at the Morgan Stanley 23rd Annual Global Healthcare Conference in New York. The session will take place on Monday, September 8, 2025, from 3:20 p.m. to 3:55 p.m., Eastern Standard Time, and can be accessed via a live webcast on the United Therapeutics website at https://ir.unither.com/events-and-presentations. An archived, recorded version of the session will be available approximately 24 hours after the session ends and can be accessed for 90

    8/29/25 7:00:00 AM ET
    $UTHR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $UTHR
    SEC Filings

    View All

    SEC Form 144 filed by United Therapeutics Corporation

    144 - UNITED THERAPEUTICS Corp (0001082554) (Subject)

    9/11/25 1:32:40 PM ET
    $UTHR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by United Therapeutics Corporation

    144 - UNITED THERAPEUTICS Corp (0001082554) (Subject)

    9/9/25 4:25:39 PM ET
    $UTHR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    United Therapeutics Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - UNITED THERAPEUTICS Corp (0001082554) (Filer)

    9/2/25 7:00:49 AM ET
    $UTHR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $UTHR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chairperson & CEO Rothblatt Martine A exercised 8,000 shares at a strike of $120.26 and sold $3,183,777 worth of shares (8,000 units at $397.97) (SEC Form 4)

    4 - UNITED THERAPEUTICS Corp (0001082554) (Issuer)

    9/11/25 7:41:09 PM ET
    $UTHR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PRESIDENT AND COO Benkowitz Michael exercised 16,375 shares at a strike of $318.55 and sold $6,481,612 worth of shares (16,375 units at $395.82) (SEC Form 4)

    4 - UNITED THERAPEUTICS Corp (0001082554) (Issuer)

    9/10/25 4:31:42 PM ET
    $UTHR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Malcolm Jan sold $280,203 worth of shares (700 units at $400.29), decreasing direct ownership by 57% to 520 units (SEC Form 4)

    4 - UNITED THERAPEUTICS Corp (0001082554) (Issuer)

    9/10/25 4:31:22 PM ET
    $UTHR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $UTHR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Cantor Fitzgerald initiated coverage on United Therapeutics with a new price target

    Cantor Fitzgerald initiated coverage of United Therapeutics with a rating of Overweight and set a new price target of $405.00

    6/2/25 8:55:47 AM ET
    $UTHR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    United Therapeutics downgraded by Wells Fargo

    Wells Fargo downgraded United Therapeutics from Overweight to Equal Weight

    4/25/25 8:31:30 AM ET
    $UTHR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    United Therapeutics upgraded by BofA Securities with a new price target

    BofA Securities upgraded United Therapeutics from Underperform to Neutral and set a new price target of $314.00

    4/21/25 8:09:51 AM ET
    $UTHR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $UTHR
    Financials

    Live finance-specific insights

    View All

    United Therapeutics Corporation to Report Second Quarter 2025 Financial Results Before Market Open on Wednesday, July 30, 2025

    United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its second quarter 2025 financial results before the market opens on Wednesday, July 30, 2025. A press release detailing the quarterly results will be issued that day at approximately 6:30 a.m. Eastern Time. United Therapeutics will host a public webcast Wednesday, July 30, 2025, at 9:00 a.m. Eastern Time. The webcast will be accessible via United Therapeutics' website at https://ir.unither.com/events-and-presentations. A rebroadcast of the webcast will be available for one year and can be accessed at the same location. United Therapeutics: Enabling Inspiration At United Therapeutics, our vision and mis

    7/16/25 7:00:00 AM ET
    $UTHR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    United Therapeutics Corporation Reports First Quarter 2025 Financial Results

    United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter ended March 31, 2025. Total revenues in the first quarter of 2025 grew 17 percent year-over-year to $794.4 million, compared to $677.7 million in the first quarter of 2024. "2025 is off to a tremendous start as we reported yet another quarter of record revenue," said Martine Rothblatt, Ph.D., Chairperson and Chief Executive Officer of United Therapeutics. "Beyond the continued execution of our foundational wave of growth in the commercial business, throughout the balance of the year we'll progress our innovation and revolution waves of growth with the readout

    4/30/25 6:30:00 AM ET
    $UTHR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    United Therapeutics Corporation to Report First Quarter 2025 Financial Results Before Market Open on Wednesday, April 30, 2025

    United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its first quarter 2025 financial results before the market opens on Wednesday, April 30, 2025. A press release detailing the quarterly results will be issued that day at approximately 6:30 a.m. Eastern Time. United Therapeutics will host a public webcast Wednesday, April 30, 2025, at 9:00 a.m. Eastern Time. The webcast will be accessible via United Therapeutics' website at https://ir.unither.com/events-and-presentations. A rebroadcast of the webcast will be available for one year and can be accessed at the same location. United Therapeutics: Enabling Inspiration At United Therapeutics, our vision and missi

    4/16/25 7:00:00 AM ET
    $UTHR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $UTHR
    Leadership Updates

    Live Leadership Updates

    View All

    IM Therapeutics Announces Appointment of Jonathan Rigby to Board of Directors

    WOBURN, Mass.--(BUSINESS WIRE)--ImmunoMolecular Therapeutics, Inc. (“IM Therapeutics”), a clinical stage company developing personalized therapies for autoimmune disease, announced today that Jonathan Rigby has joined its Board of Directors. Mr. Rigby brings extensive company building and pipeline development experience in autoimmune and other diseases. IM Therapeutics is developing small molecule oral genetic medicines targeting specific human leukocyte antigen (HLA) variants known to play a strong role in autoimmune diseases. The Company’s lead drug candidate, IMT-002, is in Phase 1b clinical trials in type 1 diabetes (T1D). Patients in the study were preselected for HLA-DQ8, the

    1/27/21 8:00:00 AM ET
    $CLGN
    $UTHR
    $XERS
    Industrial Specialties
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $UTHR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by United Therapeutics Corporation

    SC 13G/A - UNITED THERAPEUTICS Corp (0001082554) (Subject)

    11/8/24 4:30:29 PM ET
    $UTHR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by United Therapeutics Corporation

    SC 13G - UNITED THERAPEUTICS Corp (0001082554) (Subject)

    10/16/24 1:03:48 PM ET
    $UTHR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by United Therapeutics Corporation (Amendment)

    SC 13G/A - UNITED THERAPEUTICS Corp (0001082554) (Subject)

    6/10/24 12:15:17 PM ET
    $UTHR
    Biotechnology: Pharmaceutical Preparations
    Health Care